Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CERO 
CERo Therapeutics Holdings, Inc. Common Stock (CERO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $45
1 Year Target Price $45
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.99% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.25M USD | Price to earnings Ratio - | 1Y Target Price 45 |
Price to earnings Ratio - | 1Y Target Price 45 | ||
Volume (30-day avg) 2 | Beta 0.49 | 52 Weeks Range 6.71 - 896.00 | Updated Date 08/29/2025 |
52 Weeks Range 6.71 - 896.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -512.76 |
Earnings Date
Report Date 2025-08-22 | When After Market | Estimate -6.21 | Actual -61.71 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -156.89% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15169807 | Price to Sales(TTM) - |
Enterprise Value 15169807 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 1205400 | Shares Floating 1102750 |
Shares Outstanding 1205400 | Shares Floating 1102750 | ||
Percent Insiders 3.55 | Percent Institutions 25.77 |
Upturn AI SWOT
CERo Therapeutics Holdings, Inc. Common Stock
Company Overview
History and Background
CERo Therapeutics Holdings, Inc. is a pre-clinical stage biotechnology company focused on developing novel cell-based immunotherapies for cancer. Founded in 2021, the company is headquartered in San Diego, CA. Its early focus has been on developing therapies that modulate immune responses to fight cancer.
Core Business Areas
- Cell-Based Immunotherapy Development: CERo is focused on developing novel cell-based immunotherapies for the treatment of cancer.
- Research and Pre-clinical Studies: The company conducts research and pre-clinical studies to validate its therapeutic candidates.
Leadership and Structure
The company is led by a team with experience in biotechnology and oncology. The organizational structure is typical of a small, early-stage biotech company.
Top Products and Market Share
Key Offerings
- Cell-Based Immunotherapies (Pre-clinical): CERo's product candidates are in pre-clinical development and do not have market share or revenue. Competitors in the cell-based immunotherapy field include Kite Pharma (GILD), Novartis (NVS), and Bristol Myers Squibb (BMY).
Market Dynamics
Industry Overview
The cell-based immunotherapy market is rapidly growing, driven by increasing cancer incidence and advancements in immunotherapy technologies. The market is competitive with many companies developing similar therapies.
Positioning
CERo is an early-stage player in the cell-based immunotherapy market, focused on novel targets and approaches. It competes with larger, more established companies.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is estimated to reach hundreds of billions of dollars, with cell-based therapies contributing a significant portion. CERo aims to capture a share of this market through its innovative technologies, though currently not generating revenue.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced scientific team
- Potential for breakthrough therapies
Weaknesses
- Early-stage company with no approved products
- Limited financial resources
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Advancements in immunotherapy technologies
- Growing demand for effective cancer treatments
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- NVS
- BMY
Competitive Landscape
CERo faces significant competition from larger, more established pharmaceutical companies with greater resources and expertise. It needs to demonstrate its innovative technology to differentiate itself.
Growth Trajectory and Initiatives
Historical Growth: Not Applicable.
Future Projections: Future growth depends on successful clinical development and commercialization of its product candidates.
Recent Initiatives: The recent initiatives are focused on advancing its pre-clinical programs and seeking strategic partnerships.
Summary
CERo Therapeutics Holdings, Inc. is an early-stage biotech company with a focus on cell-based immunotherapies. Being in the pre-clinical stage, the company is in a high-risk, high-reward setting. Successful clinical development and partnerships are critical for its future growth. The company faces competition from established pharmaceutical companies, making technological differentiation essential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2024-02-15 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.